We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 125.23 | 305 | 11:11:15 |
From Apr 2021 to Apr 2024
By Colin Kellaher
Merck & Co. on Wednesday said the U.S. Food and Drug Administration granted priority review to its application for expanded use of its Vaxneuvance 15-valent vaccine in children six weeks through 17 years of age.
The Kenilworth, N.J., drugmaker in July received FDA approval of the vaccine for the prevention of invasive pneumococcal disease in adults.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
Merck said the agency set a target action date of April 1, 2022, for its application.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 01, 2021 07:21 ET (12:21 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
